99 related articles for article (PubMed ID: 25173108)
41. Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
Pollack CV; Levy JH; Eikelboom J; Weitz JI; Sellke FW; Huisman MV; Steiner T; Kamphuisen P; Bernstein RA
Am J Emerg Med; 2014 Nov; 32(11):1433-4. PubMed ID: 25239691
[No Abstract] [Full Text] [Related]
42. Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis.
Castellucci LA; Cameron C; Le Gal G; Rodger MA; Coyle D; Wells PS; Clifford T; Gandara E; Wells G; Carrier M
JAMA; 2014 Sep; 312(11):1122-35. PubMed ID: 25226478
[TBL] [Abstract][Full Text] [Related]
43. Current developments for the oral delivery of heparin.
Schlüter A; Lamprecht A
Curr Pharm Biotechnol; 2014; 15(7):640-9. PubMed ID: 25219865
[TBL] [Abstract][Full Text] [Related]
44. Laboratory monitoring of the non-vitamin K oral anticoagulants.
Blann AD; Lip GY
J Am Coll Cardiol; 2014 Sep; 64(11):1140-2. PubMed ID: 25212649
[No Abstract] [Full Text] [Related]
45. Pharmacology and mechanisms of action of new oral anticoagulants.
Salem JE; Sabouret P; Funck-Brentano C; Hulot JS
Fundam Clin Pharmacol; 2015 Feb; 29(1):10-20. PubMed ID: 25196680
[TBL] [Abstract][Full Text] [Related]
46. Dental implications of new oral anticoagulants for atrial fibrillation.
Curtin C; Hayes JM; Hayes J
Dent Update; 2014; 41(6):526-8, 530-1. PubMed ID: 25195485
[TBL] [Abstract][Full Text] [Related]
47. Clinical usefulness of measuring prothrombin time and soluble fibrin levels in Japanese patients with atrial fibrillation receiving rivaroxaban.
Nakano Y; Kondo T; Osanai H; Murase Y; Nakashima Y; Asano H; Ajioka M; Sakai K; Inden Y; Murohara T
J Cardiol; 2015 Mar; 65(3):185-90. PubMed ID: 25192594
[TBL] [Abstract][Full Text] [Related]
48. Once-daily edoxaban: a safer option than well-managed warfarin for patients with atrial fibrillation?
Giugliano RP
Eur Heart J; 2014 Jul; 35(28):1826-7. PubMed ID: 25184175
[No Abstract] [Full Text] [Related]
49. Concurrent pulmonary thrombosis with systemic embolism: a case report.
Xie XJ; Jiang JB; Jiang J; Wang JA
J Zhejiang Univ Sci B; 2014 Sep; 15(9):838-44. PubMed ID: 25183038
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.
Xue T; Ding S; Guo B; Zhou Y; Sun P; Wang H; Chu W; Gong G; Wang Y; Chen X; Yang Y
J Med Chem; 2014 Sep; 57(18):7770-91. PubMed ID: 25179681
[TBL] [Abstract][Full Text] [Related]
51. Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.
Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
Hosp Pract (1995); 2014 Aug; 42(3):17-25. PubMed ID: 25255403
[TBL] [Abstract][Full Text] [Related]
52. Additional events in the RE-LY trial.
Connolly SJ; Wallentin L; Yusuf S
N Engl J Med; 2014 Oct; 371(15):1464-5. PubMed ID: 25251519
[No Abstract] [Full Text] [Related]
53. Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the Rivaroxaban Postmarketing Surveillance Registry.
Ogawa S; Ikeda T; Kitazono T; Nakagawara J; Minematsu K; Miyamoto S; Murakawa Y; Iekushi K; Yamanaka S; Yamada T; Inuyama L;
J Stroke Cerebrovasc Dis; 2014; 23(10):2520-2526. PubMed ID: 25245483
[TBL] [Abstract][Full Text] [Related]
54. Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery.
Leil TA; Frost C; Wang X; Pfister M; LaCreta F
CPT Pharmacometrics Syst Pharmacol; 2014 Sep; 3(9):e136. PubMed ID: 25229619
[TBL] [Abstract][Full Text] [Related]
55. [Seronegative antiphospholipid syndrome, catastrophic syndrome, new anticoagulants: learning from a difficult case report].
Joalland F; de Boysson H; Darnige L; Johnson A; Jeanjean C; Cheze S; Augustin A; Auzary C; Geffray L
Rev Med Interne; 2014 Nov; 35(11):752-6. PubMed ID: 25217794
[TBL] [Abstract][Full Text] [Related]
56. Atrial fibrillation: a review of recent studies with a focus on those from the duke clinical research institute.
Rao MP; Pokorney SD; Granger CB
Scientifica (Cairo); 2014; 2014():901586. PubMed ID: 25215263
[TBL] [Abstract][Full Text] [Related]
57. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
Cuker A; Siegal DM; Crowther MA; Garcia DA
J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
[TBL] [Abstract][Full Text] [Related]
58. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
Incampo F; Carrieri C; Semeraro N; Colucci M
Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
[TBL] [Abstract][Full Text] [Related]
59. New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience.
Gorczyca-Michta I; Wożakowska-Kapłon B
Kardiol Pol; 2015; 73(2):85-93. PubMed ID: 25179482
[TBL] [Abstract][Full Text] [Related]
60. Clopidogrel prescription filling delays and cardiovascular outcomes in a pharmacy system integrating inpatient and outpatient care: insights from the Veterans Affairs CART Program.
Byrd JB; Maddox TM; O'Donnell CI; Grunwald GK; Bhatt DL; Tsai TT; Rumsfeld JS; Ho PM
Am Heart J; 2014 Sep; 168(3):340-5. PubMed ID: 25173546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
